ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1951

Possible Involvement of Fractalkine/CX3CR1 Axis in Peripheral CD14++CD16+ Monocytes in Disease Development of Patients with Systemic Lupus Erythematosus

Keiko Yoshimoto1, Katsuya Suzuki1, Noriyasu Seki2, Shuntaro Saito3, Jun Kikuchi1 and Tsutomu Takeuchi4, 1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 2Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan, 3Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, 4Division of Rheumatology, Department of internal Medicine, School of Medicine, Keio University, Tokyo, Japan

Meeting: ACR Convergence 2020

Keywords: Monocytes/macrophages, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 9, 2020

Session Title: Cytokines & Cell Trafficking (1948–1952)

Session Type: Abstract Session

Session Time: 3:00PM-3:50PM

Background/Purpose: Fractalkine (FKN) binds its receptor, CX3CR1 and accelerates chemotaxis of immune cells by inducing cell surface molecules and mediating adhesion of the cells to vascular endothelial cells. Several lines of evidence suggest that the FKN/CX3CR1 axis plays a crucial role in local infiltration of inflammatory cells at the sites of injury, which may result in impairments of organs in systemic lupus erythematosus (SLE). Our previous data showed that the expression level of CX3CR1 in peripheral CD14++CD16+ monocytes was remarkably decreased in SLE active patients as compared with SLE inactive patients and healthy controls (HC). In this study, we investigated the possible involvement of FKN/CX3CR1axis in immunological abnormalities and clinical features of SLE.

Methods: Fifty-nine SLE patients (SLEH; high disease activity, SLEDAI: >10, n = 32, SLEM+L; moderate and low disease activity, SLEDAI: < 10, n = 27) and 34 healthy controls (HC) were enrolled in this study. The expression level of CX3CR1 in peripheral CD14++CD16+ monocytes was analyzed by FACS using whole blood samples from patients and HC. The serum level of FKN was measured by a Slow Off-rate Modified DNA Aptamer (SOMAmer)-based capture array. Disease activities of SLE patients were quantified based on the SLEDAI scores. The serological data of the patients was collected by clinical records. Differences between the groups were examined for statistical significance by a t-test for single comparisons. Pearson’s correlation analysis was employed to evaluate the relationship between two continuous variables.

Results: FACS analysis revealed that the proportion of CX3CR1 positive cells among CD14++CD16+ monocytes was significantly lower in SLEH patients than in patients with SLEM+L (p = 0.007) or HC (p = 0.007), whereas the difference was not significant between SLEM+L and HC. Moreover, the CX3CR1+/CD14++CD16+ ratio was negatively and positively correlated with the SLEDAI score (p = 0.031) and serum level of C3 (p = 0.045), respectively, of all SLE patients. In addition, serum level of FKN was significantly higher in SLEH patients than those of SLEM+L patients (p = 0.005) and HC (p = 0.001). Interestingly, the serum FKN level was positively and negatively correlated with SLEDAI score (p = 0.0004) and C3 (p = 0.0043), respectively, of all SLE patients. Notably, the CX3CR1+/CD14++CD16+ ratio was negatively and significantly correlated with serum FKN level of the patients (p = 0.0078).

Conclusion: These results raised the possibility that reduced expression of CX3CR1 in peripheral CD14++CD16+ monocytes and the enhanced serum FKN level lead to acceleration of migration of FKN-stimulated CD14++CD16+ monocytes to organs.


Disclosure: K. Yoshimoto, None; K. Suzuki, None; N. Seki, Mitsubishi Tanabe Pharma Corporation, 3; S. Saito, Chugai Pharmaceutical Co. Ltd., 1, Eisai Co.,Ltd., 1, Pfizer Japan Inc., 1, Asahikasei Pharma Corp., 1, Bristol–Myers Squibb, 1, Mitsubishi Tanabe Pharma Co., 1; J. Kikuchi, None; T. Takeuchi, Astellas Pharma Inc., 2, 5, 8, Daiichi Sankyo Company, Limited, 2, 5, 8, Takeda Pharmaceutical Company Limited, 2, 5, 8, AbbVie GK., 2, 5, 8, Asahi Kasei Pharma Corporation, 2, 5, 8, Mitsubishi Tanabe Pharma Corporation, 2, 5, 8, Eisai Co., Ltd., 2, 5, 8, Nippon Kayaku Co., Ltd., 2, 5, 8, Chugai Pharmaceutical Co., Ltd., 2, 5, 8, Eli Lily Japan K.K, 2, 5, 8, Gilead Sciences, Inc., 2, 5, 8, Pfizer Japan, Inc., 2, 5, 8, Bristol-Myers Squibb, 2, 5, 8, AYUMI Pharmaceutical Corporation, 2, 5, 8, Novartis Pharma K.K., 2, 5, 8, UCB, 2, 5, 8, Dainippon Sumitomo Co., 2, 5, 8, Shionogi & Co., Ltd., 2, 5, 8.

To cite this abstract in AMA style:

Yoshimoto K, Suzuki K, Seki N, Saito S, Kikuchi J, Takeuchi T. Possible Involvement of Fractalkine/CX3CR1 Axis in Peripheral CD14++CD16+ Monocytes in Disease Development of Patients with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/possible-involvement-of-fractalkine-cx3cr1-axis-in-peripheral-cd14cd16-monocytes-in-disease-development-of-patients-with-systemic-lupus-erythematosus/. Accessed January 17, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/possible-involvement-of-fractalkine-cx3cr1-axis-in-peripheral-cd14cd16-monocytes-in-disease-development-of-patients-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.